静注用人免疫グロブリン製剤（IVIG）使用の実態調査 二次調査 小腸

上野 豪久; 高瀬 洪生; 工藤 博典; 和田 基; 奥山 宏臣; 中川 健; 江川 裕人

doi:10.11386/jst.59.1_1

A survey for intravenous immunoglobulin (IVIG) for intestinal transplantation in Japan: secondary survey report

Takehisa UENO, Koki TAKASE, Hironori KUDO, Motoshi WADA, Hiroomi OKUYAMA, Ken NAKAGAWA, Hiroto EGAWA

Author information

Keywords: anti-body mediated rejection, chronic rejection, donor specific antibody, human leukocyte antigen, small bowel transplantation

JOURNAL FREE ACCESS

2024 Volume 59 Issue 1 Pages 1-5

DOI https://doi.org/10.11386/jst.59.1_1

Details

Abstract

A preliminary survey for cases treated with intravenous immunoglobulin (IVIG) for Antibody-mediated rejection (AMR) in Japan was performed in 2022. Three cases treated with IVIG were reported. A secondary survey on the three cases was conducted in this study.

Intestine transplantation was performed in 42 cases from 2001 to 2022 in Japan, and IVIG was used in 3 of these cases (7%) for AMR that developed after transplantation. Five g of IVIG per dose was administrated, and the duration of administration was 6-10 days.

IVIG administration may be necessary as a therapeutic agent in intestine transplantation because of the high incidence of chronic rejection and its significant impact on prognosis. Therefore, we hope for national insurance coverage for IVIG.

Corresponding author

Register with J-STAGE for free!